Alnylam Unveils 'Alnylam 2030' Strategy Targeting 25% CAGR Through 2030
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ALNY?
Source: NASDAQ.COM
- Strategic Vision: Alnylam has unveiled its five-year 'Alnylam 2030' strategy aimed at achieving leadership in ATTR amyloidosis through sustainable innovation, thereby driving long-term growth and ensuring financial discipline.
- Revenue Growth Target: The company anticipates a compound annual growth rate (CAGR) exceeding 25% by 2030, while targeting a non-GAAP operating margin of around 30% to ensure sustained profitable growth.
- Product Revenue Performance: For Q4 2025, global net product revenues for AMVUTTRA and ONPATTRO were approximately $827 million and $32 million, respectively, together reflecting a robust 151% year-over-year growth, indicating strong market demand.
- Future Product Pipeline: Alnylam plans to launch its next-generation drug nucresiran by 2028 and aims to achieve revenue leadership in the TTR market by 2030, further expanding its clinical pipeline to over 40 programs, showcasing its innovation capabilities and market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 313.790
Low
351.00
Averages
479.53
High
580.00
Current: 313.790
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ETF Analysis: FDG Implies 18.96% Upside Potential
- FDG ETF Potential: The American Century Focused Dynamic Growth ETF (FDG) has an implied analyst target price of $152.53 per unit, while trading at $128.22, indicating an 18.96% upside potential that reflects market optimism about the ETF's future performance.
- HubSpot Price Analysis: HubSpot Inc (HUBS) is currently priced at $214.69, with an analyst target of $336.16, suggesting a significant 56.58% upside, indicating analysts' positive outlook on its growth prospects.
- Reddit Investment Outlook: Reddit Inc (RDDT) trades at $152.96, with a target price of $223.03, representing a 45.81% potential increase, reflecting market confidence in its business outlook.
- Alnylam Growth Expectations: Alnylam Pharmaceuticals Inc (ALNY) is priced at $313.79, with an analyst target of $450.22, indicating a 43.48% upside, showcasing analysts' optimism regarding its future performance.
See More
Transformation of Value in Biotechnology Sector
- Value Shift: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset rather than just research expenditure, reinforced by fair-value accounting under U.S. GAAP that allows companies to reflect clinical advancements and commercialization timing on their balance sheets.
- Investment Opportunities in Clinical Assets: Institutional investors are increasingly recognizing the investment value of clinical-stage biotech assets, even in the absence of current revenue, as Oncotelic Therapeutics exemplifies how scientific progress can directly influence financial positioning, significantly enhancing enterprise valuation through its diversified pipeline and 45% stake in GMP Bio.
- Clinical Development Drives Valuation: As drug candidates advance through clinical development, their value significantly increases due to rising probabilities of success and proximity to commercialization, particularly for late-stage assets nearing regulatory approval, which tend to command a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and Manufacturing Convergence: AI-driven drug development and GMP-compliant manufacturing platforms are accelerating timelines and improving scalability across the biotech industry, with Oncotelic Therapeutics demonstrating how to integrate oncology drug development with AI platforms, thereby linking scientific advancement with financial valuation and positioning the company favorably in the rapidly evolving biotech landscape.
See More
Biotechnology Sector Undergoes Value Transformation
- Value Transformation Trend: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset, particularly as drug candidates approach commercialization, significantly enhancing companies' balance sheet values.
- Fair Value Accounting Implementation: The adoption of fair-value accounting under U.S. GAAP allows life sciences companies to incorporate clinical progress, probability of success, and commercialization timing into financial reporting, thereby increasing transparency and attracting institutional investors to clinical-stage biotech assets.
- Clinical Progress Drives Valuation: As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization, with late-stage assets commanding a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and GMP Manufacturing Convergence: The integration of AI-driven drug development and GMP-compliant manufacturing accelerates timelines and enhances scalability across the biotech industry, improving clinical development efficiency and market readiness, further driving the alignment of scientific progress with financial valuation.
See More
CGGR Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGGR's 52-week low is $31.33 per share, with a high of $45.835, and the latest trade at $44.81 indicates the stock is nearing its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with a useful technical analysis perspective, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market trends.
See More
Vutrisiran Enhances Quality of Life for ATTR-CM Patients
- Significant Treatment Effects: Vutrisiran demonstrated substantial improvements in health-related quality of life for ATTR-CM patients in the HELIOS-B analysis, particularly in physical limitations and overall quality of life, with effects comparable to those seen in younger patients, reinforcing its efficacy and durability as a first-line treatment.
- High Adherence Data: Real-world data indicated that 93.8% of patients remained adherent to Vutrisiran treatment after 12 months, with a mean follow-up of 613.8 days, showcasing the drug's excellent tolerability and persistence in clinical practice.
- Reduced Risk of Disease Progression: The HELIOS-B double-blind analysis revealed that Vutrisiran significantly lowered the risk of patients progressing to advanced disease, with only 8.0% of treated patients transitioning to NYHA class III or higher, compared to 10.7% in the placebo group, indicating a clear therapeutic advantage.
- Favorable Safety Profile: Vutrisiran exhibited a favorable safety profile in patients with advanced disease, with a similar or lower incidence of adverse events compared to the placebo group, further supporting its potential for use in high-risk patients.
See More
Alnylam Advances Early Diagnosis and Care for ATTR-CM
- Early Diagnosis Strategy: Alnylam collaborates with Viz.ai and the American Heart Association to launch an AI-driven care pathway for ATTR-CM, aiming to accelerate patient identification through an FDA-approved AI algorithm, thereby enhancing diagnostic efficiency and improving patient care quality.
- Clinical Research Initiative: The AWARE study will evaluate the integration of AI screening into clinical workflows, with the goal of generating empirical data across five pilot health systems to support broader adoption of AI technologies and improve diagnostic timelines for ATTR-CM.
- System of Care Improvement: Alnylam supports a three-year initiative led by the American Heart Association, convening a cohort of 10 multidisciplinary health systems to identify care gaps and share best practices, optimizing the diagnosis and management processes for ATTR-CM patients.
- Commitment to Long-Term Impact: Through these initiatives, Alnylam aims not only to enhance early recognition of ATTR-CM but also to ensure timely interventions for patients through systemic collaboration and technological innovation, ultimately improving long-term health outcomes.
See More
ETF Analysis: FDG Implies 18.96% Upside Potential
- FDG ETF Potential: The American Century Focused Dynamic Growth ETF (FDG) has an implied analyst target price of $152.53 per unit, while trading at $128.22, indicating an 18.96% upside potential that reflects market optimism about the ETF's future performance.
- HubSpot Price Analysis: HubSpot Inc (HUBS) is currently priced at $214.69, with an analyst target of $336.16, suggesting a significant 56.58% upside, indicating analysts' positive outlook on its growth prospects.
- Reddit Investment Outlook: Reddit Inc (RDDT) trades at $152.96, with a target price of $223.03, representing a 45.81% potential increase, reflecting market confidence in its business outlook.
- Alnylam Growth Expectations: Alnylam Pharmaceuticals Inc (ALNY) is priced at $313.79, with an analyst target of $450.22, indicating a 43.48% upside, showcasing analysts' optimism regarding its future performance.
See More
Transformation of Value in Biotechnology Sector
- Value Shift: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset rather than just research expenditure, reinforced by fair-value accounting under U.S. GAAP that allows companies to reflect clinical advancements and commercialization timing on their balance sheets.
- Investment Opportunities in Clinical Assets: Institutional investors are increasingly recognizing the investment value of clinical-stage biotech assets, even in the absence of current revenue, as Oncotelic Therapeutics exemplifies how scientific progress can directly influence financial positioning, significantly enhancing enterprise valuation through its diversified pipeline and 45% stake in GMP Bio.
- Clinical Development Drives Valuation: As drug candidates advance through clinical development, their value significantly increases due to rising probabilities of success and proximity to commercialization, particularly for late-stage assets nearing regulatory approval, which tend to command a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and Manufacturing Convergence: AI-driven drug development and GMP-compliant manufacturing platforms are accelerating timelines and improving scalability across the biotech industry, with Oncotelic Therapeutics demonstrating how to integrate oncology drug development with AI platforms, thereby linking scientific advancement with financial valuation and positioning the company favorably in the rapidly evolving biotech landscape.
See More
Biotechnology Sector Undergoes Value Transformation
- Value Transformation Trend: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset, particularly as drug candidates approach commercialization, significantly enhancing companies' balance sheet values.
- Fair Value Accounting Implementation: The adoption of fair-value accounting under U.S. GAAP allows life sciences companies to incorporate clinical progress, probability of success, and commercialization timing into financial reporting, thereby increasing transparency and attracting institutional investors to clinical-stage biotech assets.
- Clinical Progress Drives Valuation: As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization, with late-stage assets commanding a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and GMP Manufacturing Convergence: The integration of AI-driven drug development and GMP-compliant manufacturing accelerates timelines and enhances scalability across the biotech industry, improving clinical development efficiency and market readiness, further driving the alignment of scientific progress with financial valuation.
See More
CGGR Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGGR's 52-week low is $31.33 per share, with a high of $45.835, and the latest trade at $44.81 indicates the stock is nearing its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with a useful technical analysis perspective, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market trends.
See More
Vutrisiran Enhances Quality of Life for ATTR-CM Patients
- Significant Treatment Effects: Vutrisiran demonstrated substantial improvements in health-related quality of life for ATTR-CM patients in the HELIOS-B analysis, particularly in physical limitations and overall quality of life, with effects comparable to those seen in younger patients, reinforcing its efficacy and durability as a first-line treatment.
- High Adherence Data: Real-world data indicated that 93.8% of patients remained adherent to Vutrisiran treatment after 12 months, with a mean follow-up of 613.8 days, showcasing the drug's excellent tolerability and persistence in clinical practice.
- Reduced Risk of Disease Progression: The HELIOS-B double-blind analysis revealed that Vutrisiran significantly lowered the risk of patients progressing to advanced disease, with only 8.0% of treated patients transitioning to NYHA class III or higher, compared to 10.7% in the placebo group, indicating a clear therapeutic advantage.
- Favorable Safety Profile: Vutrisiran exhibited a favorable safety profile in patients with advanced disease, with a similar or lower incidence of adverse events compared to the placebo group, further supporting its potential for use in high-risk patients.
See More
Alnylam Advances Early Diagnosis and Care for ATTR-CM
- Early Diagnosis Strategy: Alnylam collaborates with Viz.ai and the American Heart Association to launch an AI-driven care pathway for ATTR-CM, aiming to accelerate patient identification through an FDA-approved AI algorithm, thereby enhancing diagnostic efficiency and improving patient care quality.
- Clinical Research Initiative: The AWARE study will evaluate the integration of AI screening into clinical workflows, with the goal of generating empirical data across five pilot health systems to support broader adoption of AI technologies and improve diagnostic timelines for ATTR-CM.
- System of Care Improvement: Alnylam supports a three-year initiative led by the American Heart Association, convening a cohort of 10 multidisciplinary health systems to identify care gaps and share best practices, optimizing the diagnosis and management processes for ATTR-CM patients.
- Commitment to Long-Term Impact: Through these initiatives, Alnylam aims not only to enhance early recognition of ATTR-CM but also to ensure timely interventions for patients through systemic collaboration and technological innovation, ultimately improving long-term health outcomes.
See More
